The intersection of CRISPR technologies with preamplification methods for disease diagnosis is a dynamic and rapidly growing area of research, driven by the need for sensitive, specific, and rapid diagnostic tools for various diseases including infectious diseases and cancers. Many diagnostic methods based on CRISPR require preamplification to detect lowabundance nucleic acids. 56% of publications appear to be associated with PCR as a preamplification technique in combination with CRISPR diagnostics to achieve low-cost and pointof-care solutions. This is followed by recombinase polymerase amplification (RPA) (18%) and loop-mediated isothermal amplification (LAMP) (7%) etc. Recent publications are also exploring non-amplification methods (4%), focusing on simpler, faster and more portable diagnostic systems (Figure ). Various readout methods are used to interpret the results of CRISPR diagnostics, ranging from simple colorimetric assays to more complex fluorescence-based systems. Fluorescence and sequencing readouts dominate the landscape (39% and 33% respectively), with growing interest in lateral flow, electrochemical, colorimetric, luminescence and optical (Figure ). Abbreviations used: PCR, polymerase chain reaction; RPA, recombinase polymerase amplification; LAMP, loop-mediated isothermal amplification; RCA, rolling circle amplification; RAA, recombinase-aided amplification; HCR, hybridization chain reaction; NASBA, nucleic acid sequence-based amplification; SDA, strand-displacement amplification; EXPAR, exponential amplification reaction; HAD, helicase-dependent amplification.